This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

ACE Inhibitor Boosts Coronary Circulation in Diabetics

Posted: Tuesday, April 25, 2006

Researchers reported that angiotensin-converting enzyme (ACE) inhibitors can improve coronary flow velocity reserve (CFVR) in patients with type 2 diabetes.

However, the researchers found that treatment with the angiotensin II type 1 receptor antagonist candesartan did not affect CFVR.

Both types of drugs have shown evidence of benefit in diabetic patients, Dr. Takayuki Kawata of Chiba University Graduate School of Medicine and colleagues write. Acute infusion of ACE inhibitors has been shown to increase coronary perfusion in diabetic patients, they add, but it is not clear whether the two drugs' effects on coronary circulation in these patients are similar.

To investigate, the researchers randomly assigned 24 patients with type 2 diabetes to 2 mg per day of the ACE inhibitor temocapril or 8 mg per day of candesartan. CFVR was calculated at the beginning of the study and after four weeks of treatment. It was also measured in eight healthy controls.

CFVR before treatment was 2.74 for patients in the temocapril group and 2.65 for patients on candesartan. It was 3.53 in the controls. After treatment, CFVR rose to 3.31 in the temocapril group, but remained the same in the candesartan group. Both drugs produced a similar reduction in blood pressure.

The findings suggest that temocapril's effects on coronary circulation in diabetic patients are independent of angiotensin antagonism, Dr. Kawata and his team note. The drug could improve coronary circulation by increasing bradykinin availability, the researchers suggest.

Thus they conclude that ACE inhibitors, but not angiotensin II type 1 receptor antagonists "may have beneficial effects on the coronary microangiopathy associated with type 2 diabetes mellitus."

Source: Diabetes In Control: Am Heart J 2006;151:798.e9-798.e15